07/24/2025
“Longevity is a bigger market opportunity than obesity.” – Jay Olson, Oppenheimer
The same way GLP-1s exploded the obesity market into a Wall Street darling, longevity is next. Jay Olson nails it: we’re going from theory to therapy right now—and early investors have a rare moment to get in before the street catches on.
At 15:50, Jay spotlights Sen-Jam’s platform—a patented, de-risked combo therapy repurposing two proven drugs, squarely positioned in metabolic restoration, a key subsector he calls “king.” 👑
“This is one of the most exciting but least understood investment areas today… the opportunity is NOW.”
🎧 Listen to the full 20-min podcast: https://lnkd.in/e7KbsTkj
Own an Early Piece of the Longevity Play
🔗 Invest now https://bit.ly/44b0gne
